Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Down 31.3% in February

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 96,000 shares, a decrease of 31.3% from the February 13th total of 139,800 shares. Based on an average trading volume of 309,400 shares, the short-interest ratio is currently 0.3 days. Approximately 2.1% of the shares of the company are short sold.

Entero Therapeutics Price Performance

Shares of NASDAQ:ENTO traded up $0.03 during trading on Monday, hitting $0.51. 77,602 shares of the stock were exchanged, compared to its average volume of 395,784. Entero Therapeutics has a 1-year low of $0.19 and a 1-year high of $3.16. The company’s fifty day simple moving average is $0.53 and its 200-day simple moving average is $0.52.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.